<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871594</url>
  </required_header>
  <id_info>
    <org_study_id>M21TUR</org_study_id>
    <nct_id>NCT04871594</nct_id>
  </id_info>
  <brief_title>Checkpoint Inhibition With or Without Domatinostat in Urothelial Cancer</brief_title>
  <acronym>TURANDOT</acronym>
  <official_title>DOmaTinostat, Nivolumab and Ipilimumab A Phase 1b Study in Stage II-III URothelial cANcer to Explore Pre-operative - TURANDOT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>4SC AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study of the addition of domatinostat to pre-operative immune&#xD;
      checkpoint inhibitors in patients with muscle invasive urothelial cancer. This study can be&#xD;
      adapted or expanded to a phase 2 study based on results obtained.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1b safety, feasibility and proof-of-principle study of the addition of&#xD;
      domatinostat to pre-operative immune checkpoint inhibition (CPI) with nivolumab and&#xD;
      ipilimumab.&#xD;
&#xD;
      Urothelial cancer patients will be included that are diagnosed with either:&#xD;
&#xD;
        -  cT2-4aN0M0 OR&#xD;
&#xD;
        -  cT1-4aN1-3M0&#xD;
&#xD;
      PD-L1 status will determine the treatment cohort. Within each cohort, patients will be&#xD;
      randomized to receive CPI + domatinostat or CPI alone&#xD;
&#xD;
      Cohort A (PD-L1 CPS≥10% pts):&#xD;
&#xD;
        -  Arm A1: Domatinostat 200mg BID d1-56 + nivolumab 240 mg, q3wk, day 1, 22, 43&#xD;
&#xD;
        -  Arm A2: 3x nivolumab 240 mg, q3wk, day 1, 22, 43&#xD;
&#xD;
      Cohort B (PD-L1 CPS&lt;10% pts):&#xD;
&#xD;
        -  Arm B1: Domatinostat 200mg QD d1-56 + ipilimumab 240 mg day 1, ipilimumab 240 mg +&#xD;
           nivolumab 80 mg day 22, nivolumab 240 mg, day 43&#xD;
&#xD;
        -  Arm B2: ipilimumab 240 mg day 1, ipilimumab 240 mg + nivolumab 80 mg day 22, nivolumab&#xD;
           240 mg, day 43&#xD;
&#xD;
      The primary endpoint is feasibility of neo-adjuvant domatinostat + nivolumab +/- ipilimumab&#xD;
      defined by percentage of patients who are able to have surgical resection within 12 weeks&#xD;
      from start of treatment as this is an endpoint that is clinically meaningful for this&#xD;
      population.&#xD;
&#xD;
      After surgery, patients attend study visits at day 8 and at day 29. Their final study visit&#xD;
      for physical examination and laboratory testing is at day 57 (+/- 7 days), which is scheduled&#xD;
      to anticipate late-onset adverse events. 90 days postoperative, patients will be contacted by&#xD;
      phone to evaluate surgical complications according to the Clavien-dindo classification. After&#xD;
      this phone call, patients will be followed according to standard clinical guidelines. Tumor&#xD;
      biopsies/material preservation is required at baseline and during surgery.&#xD;
&#xD;
      Main secondary endpoints are:&#xD;
&#xD;
        -  Efficacy, defined as pathological complete response (pCR) (pT0N0 or pTisN0)&#xD;
&#xD;
        -  Provide an estimate of all grade toxicities&#xD;
&#xD;
        -  Relapse free survival (RFS) and overall survival (OS) An important additional secondary&#xD;
           endpoint is translational. RNA signatures associated with pathological response and RFS&#xD;
           will be determined, as well as characterization of changes in immune infiltrates between&#xD;
           baseline and resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, open-label phase 1b clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility to complete pre-operative treatment and surgical resection within 12 weeks</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Percentage of patients that underwent surgery within 12 weeks after study start will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of domatinostat and immunotherapy</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Efficacy of domatinostat and immunotherapy, assessed by the percentage of pathological complete response rate (pCR) after cystectomy pCR rate after cystectomy according to pathological response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of domatinostat and immunotherapy</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>All grade immune-related toxicity will be compared between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival and overall survival</measure>
    <time_frame>Untill 3 years postoperative</time_frame>
    <description>During follow-up, every 6 months untill 3 years postoperative, relapse free survival will be evaluated. Overall survival will be evaluated by phone calls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitor peri-surgical complications</measure>
    <time_frame>Untill 90 days after surgery</time_frame>
    <description>Peri-operative complications and morbidity will be graded according to the Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in immune infiltrates in responders vs nonresponders</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Resistance mechanisms are explored by comparing immune (cell) infiltrates in responders and nonresponders in pre- and post treatment tissue [Multiplex immunohistochemistry, RNA seq]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>As part of regular follow-up after radical surgery, follow-up CT scans will we be made after 1 and 2 years.</measure>
    <time_frame>After 6, 12, and 24 months postoperatively, a CT-scan will be performed to evaluate disease recurrence in order to report on recurrence-free survival.</time_frame>
    <description>As part of regular follow-up after radical surgery, follow-up CT scans will we be made after 1 and 2 years. Additional scans should be performed according to local standards.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort A1: domatinostat + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1-56: domatinostat 200 mg BID Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A 2: nivolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1: domatinostat + ipilimumab + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1-56: domatinostat 200 mg QD Day 1: ipilimumab 240 mg Day 22: ipilimumab 240mg + nivolumab 80 mg Day 43: nivolumab 240 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2: ipilimumab + nivolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1: ipilimumab 240 mg Day 22: ipilimumab 240mg + nivolumab 80 mg Day 43: nivolumab 240 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domatinostat</intervention_name>
    <description>Cohort A1: day 1-56 200mg BID Cohort B1: day 1-56 200mg QD</description>
    <arm_group_label>Cohort A1: domatinostat + nivolumab</arm_group_label>
    <arm_group_label>Cohort B1: domatinostat + ipilimumab + nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Cohort A1: day 1, 22, and 43 240mg Cohort A2: day 1, 22, and 43 240mg Cohort B1: day 22 80mg, day 43 240mg Cohort B2: day 22 80mg, day 43 240mg</description>
    <arm_group_label>Cohort A 2: nivolumab</arm_group_label>
    <arm_group_label>Cohort A1: domatinostat + nivolumab</arm_group_label>
    <arm_group_label>Cohort B1: domatinostat + ipilimumab + nivolumab</arm_group_label>
    <arm_group_label>Cohort B2: ipilimumab + nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Cohort B1: day 1 240mg, day 22 240mg Cohort B2: day 1 240mg, day 22 240mg</description>
    <arm_group_label>Cohort B1: domatinostat + ipilimumab + nivolumab</arm_group_label>
    <arm_group_label>Cohort B2: ipilimumab + nivolumab</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Resectable muscle-invasive UC (upper urinary tract allowed), defined as: cT2-4aN0M0 OR&#xD;
             cT1-4aN1-3M0&#xD;
&#xD;
          -  World Health Organization (WHO) performance Status 0 or 1.&#xD;
&#xD;
          -  Urothelial cancer is the dominant histology (&gt;70%).&#xD;
&#xD;
          -  Formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks from&#xD;
             diagnostic TUR available (or equivalent FFPE tumor specimens for upper tract tumors;&#xD;
             at least two biopsy cores available).&#xD;
&#xD;
          -  PD-L1 status must be determined&#xD;
&#xD;
          -  Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L,&#xD;
             Neutrophils ≥1.0x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, GFR&gt;30 ml/min&#xD;
             as per Cockcroft-Gault formula, AST ≤ 1.5 x ULN, ALT ≤1.5 x ULN, Bilirubin ≤1.5 X ULN&#xD;
&#xD;
          -  Negative pregnancy test (βHCG in urine or blood) for female patients of childbearing&#xD;
             potential within 2 weeks prior to Day 1 Cycle 1.&#xD;
&#xD;
          -  Highly effective contraception for both male and female subjects if the risk of&#xD;
             conception exists. Female patients of childbearing potential must have a negative&#xD;
             urine or serum pregnancy test before receiving the first dose of study medication and&#xD;
             must comply with contraception methods as requested by the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with active autoimmune disease in the past 2 years. Patients with diabetes&#xD;
             mellitus, properly controlled hypothyroidism or hyperthyroidism, vitiligo, psoriasis&#xD;
             or other mild skin disease can still be included.&#xD;
&#xD;
          -  Documented history of severe autoimmune disease (e.g. inflammatory bowel disease,&#xD;
             myasthenia gravis).&#xD;
&#xD;
          -  Prior CTLA-4 or PD-1/PD-L1-targeting immunotherapy.&#xD;
&#xD;
          -  Known history of Human Immunodeficiency Virus infection or tuberculosis, or other&#xD;
             active infection requiring therapy at the time of inclusion.&#xD;
&#xD;
          -  Positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA)&#xD;
&#xD;
          -  Underlying medical conditions that, in the investigator's opinion, will make the&#xD;
             administration of study drug hazardous or obscure the interpretation of adverse events&#xD;
&#xD;
          -  Medical condition requiring the use of immunosuppressive medications, with the&#xD;
             exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at&#xD;
             physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent&#xD;
             corticosteroid. Steroids as premedication for hypersensitivity reactions (e.g., CT&#xD;
             scan premedication) will be allowed.&#xD;
&#xD;
          -  Use of other investigational drugs five half lives before study drug administration&#xD;
&#xD;
          -  Malignancy, other than urothelial cancer, in the previous 2 years, with a high chance&#xD;
             of recurrence (estimated &gt;10%). Patients with low risk prostate cancer (defined as&#xD;
             Stage T1/T2a, Gleason score ≤ 6, and PSA ≤ 10 ng/mL) who are treatment-naive and&#xD;
             undergoing active surveillance are eligible.&#xD;
&#xD;
          -  Pregnant and lactating female patients.&#xD;
&#xD;
          -  Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for&#xD;
             a major surgical procedure during the course of the study other than for diagnosis.&#xD;
&#xD;
          -  Severe infections within 2 weeks prior to enrolment in the study including but not&#xD;
             limited to hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia.&#xD;
&#xD;
          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class II or greater), myocardial infarction within 3 months prior to enrolment,&#xD;
             unstable arrhythmias and unstable angina.&#xD;
&#xD;
          -  Conditions requiring systemic anti-arrhythmic therapy known to prolong QT/QTc&#xD;
             interval.&#xD;
&#xD;
          -  Patients with QTcF interval &gt;480 msec on at least two separate and consecutive ECGs at&#xD;
             screening or a medical history of long-QT-Syndrome.&#xD;
&#xD;
          -  Previous intravenous chemotherapy for bladder cancer. Prior low-dose sensitizing&#xD;
             chemotherapy used for combined modality treatment, or radiation alone, is allowed if&#xD;
             patients have recurred after an initial response. Patients with residual disease after&#xD;
             (chemo)radiation for bladder cancer are not eligible.&#xD;
&#xD;
          -  Patients in whom use of a colon segment for urinary diversion is planned.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>M.S. van der Heijden, Dr.</last_name>
    <phone>020-512 9111</phone>
    <email>ms.vd.heijden@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.S. van der Heijden, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>T. van der Hulle, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>N. Mehra, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.B.M. Suelmann, Drs.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

